Back | Next |
home / stock / okyo / okyo message board
Subject | By | Source | When |
---|---|---|---|
Seems ready | Count Crypto | investorshub | 09/29/2023 9:14:15 PM |
seems ready? | Count Crypto | investorshub | 09/29/2023 9:01:32 PM |
$OKYO Lets go go go go... Up up and away we go. | mfayman | investorshub | 09/29/2023 8:08:55 PM |
$OKYO bears and bulls | Count Crypto | investorshub | 09/29/2023 7:54:20 PM |
$OKYO oh yeah news for the day | Sirpeter | investorshub | 09/29/2023 7:50:31 PM |
$OKYO Price trading | mfayman | investorshub | 09/29/2023 5:33:33 PM |
Price trading | mfayman | investorshub | 09/29/2023 4:57:10 PM |
what does this mean? | mfayman | investorshub | 09/29/2023 2:12:09 PM |
Price trading | StocksNcash | investorshub | 09/29/2023 1:58:48 PM |
$OKYO What do you make of this? | mfayman | investorshub | 09/29/2023 1:39:02 PM |
$OKYO Found an interesting article | mfayman | investorshub | 09/29/2023 12:07:59 PM |
Have a look at this | Count Crypto | investorshub | 09/29/2023 11:28:04 AM |
$OKYO what does this mean? | StocksNcash | investorshub | 09/29/2023 11:02:57 AM |
$OKYO The now last up | Ryguy008 | investorshub | 09/29/2023 9:06:49 AM |
When is this gonna take off? | Count Crypto | investorshub | 09/29/2023 8:56:56 AM |
$OKYO MomentumIts now | Pisd | investorshub | 09/29/2023 7:57:16 AM |
Price now last trade up | Pisd | investorshub | 09/29/2023 6:45:43 AM |
$OKYO good read | Boris the Spider | investorshub | 09/29/2023 5:45:25 AM |
short squeeze signal | mfayman | investorshub | 09/29/2023 5:35:24 AM |
$OKYO The gaining | mfayman | investorshub | 09/29/2023 4:25:34 AM |
News, Short Squeeze, Breakout and More Instantly...
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...